#1 Clinical Trials Search in Europe

Sodium Chloride Ph. Eur.

This article explores the use of Sodium Chloride Ph. Eur. in clinical trials for two distinct medical conditions: Interstitial Lung Disease (ILD) and Propionic Acidemia (PA). We’ll examine how this common substance is being utilized in combination with other drugs to potentially improve patient outcomes in these complex disorders. The trials discussed here aim to evaluate the safety and efficacy of new treatment approaches for patients suffering from these challenging conditions.

Table of Contents

What is SODIUM CHLORIDE PH. EUR.?

SODIUM CHLORIDE PH. EUR. is a pharmaceutical-grade sodium chloride solution, also known as saline solution. It’s a sterile, isotonic solution primarily composed of sodium chloride (salt) and water. The “PH. EUR.” in the name stands for “European Pharmacopoeia,” indicating that it meets the quality standards set by this official European publication for medicines[1].

Uses of SODIUM CHLORIDE PH. EUR.

SODIUM CHLORIDE PH. EUR. has various medical applications:

  • Fluid and Electrolyte Replacement: It’s commonly used to replace lost fluids and maintain electrolyte balance in the body[1].
  • Comparator in Clinical Trials: In some studies, it serves as a comparator or control substance to evaluate the effectiveness of other medications[1].
  • Auxiliary Medication: It can be used as an auxiliary or supporting medication in various treatments[2].
  • Diluent: It’s often used to dilute or dissolve other medications for intravenous administration.

How is SODIUM CHLORIDE PH. EUR. Administered?

SODIUM CHLORIDE PH. EUR. is typically administered through the following routes:

  • Direct Intravenous Injection: The solution is injected directly into a vein[1].
  • Intravenous Infusion: It can be given as a slow drip into a vein over a period of time[2].

The exact dosage and administration method will depend on the specific medical situation and will be determined by a healthcare professional.

Composition

SODIUM CHLORIDE PH. EUR. is not just simple salt water. It contains several components:

  • Sodium Chloride PH. EUR.: The primary active ingredient, which is pharmaceutical-grade salt.
  • Potassium Chloride PH. EUR.: Helps maintain proper electrolyte balance.
  • Sodium Hydrogen Carbonate PHEUR: Also known as sodium bicarbonate, it helps regulate pH levels.
  • Glucose Anhydrous PH EUR: A form of sugar that provides energy and helps with the absorption of the solution[1][2].

Current Clinical Trials

SODIUM CHLORIDE PH. EUR. is currently being used in several clinical trials:

  • Interstitial Lung Disease Study: In this trial, it’s being used as a comparator to evaluate the effectiveness of rituximab in patients with progressive Interstitial Lung Disease (ILD)[1].
  • Propionic Acidemia Study: Here, it’s being used as an auxiliary medication in a study evaluating a new treatment for Propionic Acidemia, a rare genetic disorder[2].

Safety Considerations

While SODIUM CHLORIDE PH. EUR. is generally considered safe, it’s important to note:

  • It should only be used under medical supervision.
  • Proper dosage is crucial to maintain electrolyte balance.
  • Patients with certain conditions (like heart or kidney problems) may need special monitoring when receiving this solution.
  • Always inform your healthcare provider about all medications you’re taking and any medical conditions you have before receiving SODIUM CHLORIDE PH. EUR.

Remember, this information is for educational purposes only and should not replace professional medical advice. Always consult with a healthcare provider for specific medical guidance.

Aspect EvER-ILD 2 Trial (ILD) mRNA-3927 Trial (PA)
Primary Condition Interstitial Lung Disease Propionic Acidemia
Main Treatment Rituximab mRNA-3927
Use of Sodium Chloride Ph. Eur. Part of infusion solution Part of infusion solution
Primary Outcome Change in Forced Vital Capacity Safety (Part 1), Frequency of MDEs (Part 2)
Trial Duration 6 months 20-40 weeks (Part 1), 12 months (Part 2)
Key Secondary Outcomes Progression-free survival, quality of life Changes in biomarkers, protein intake, quality of life

FAQ

  • What is Sodium Chloride Ph. Eur. and how is it used in these clinical trials? Sodium Chloride Ph. Eur. is pharmaceutical-grade salt solution. In these trials, it's used as part of an infusion solution, often in combination with other substances like potassium chloride, sodium hydrogen carbonate, and glucose. It serves as a vehicle for delivering other medications or maintaining fluid balance in patients.
  • What is Interstitial Lung Disease (ILD) and how is it being treated in the EvER-ILD 2 trial? Interstitial Lung Disease is a group of disorders causing inflammation and scarring of lung tissue. In the EvER-ILD 2 trial, researchers are testing rituximab, an antibody treatment, to see if it can improve lung function in patients with progressive ILD that has an inflammatory component.
  • What is Propionic Acidemia (PA) and how is it being addressed in the mRNA-3927 trial? Propionic Acidemia is a rare genetic disorder affecting the body's ability to break down certain proteins and fats. The mRNA-3927 trial is testing a new treatment that aims to provide the instructions for making the enzyme that PA patients lack, potentially reducing the frequency of metabolic crises.
  • How long do these clinical trials last? The EvER-ILD 2 trial evaluates patients over a 6-month period. The mRNA-3927 trial for PA has two parts: Part 1 lasts 20 to 40 weeks, while Part 2 lasts approximately 12 months, followed by a follow-up period.
  • What are the main outcomes these trials are measuring? The EvER-ILD 2 trial primarily measures changes in lung function (Forced Vital Capacity). The mRNA-3927 trial for PA focuses on safety and tolerability in Part 1, and the frequency of metabolic decompensation events in Part 2, along with various other health indicators and quality of life measures.

Ongoing Clinical Trials on Sodium Chloride Ph. Eur.

  • A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Italy The Netherlands +1

  • A Study Testing Erector Spinae Plane Block with Ropivacaine versus Placebo for Pain Relief in Adults with Acute Kidney Stone Pain in the Emergency Department

    Recruiting

    3 1 1
    Investigated drugs:
    The Netherlands

  • Study on Rituximab for Patients with Rheumatoid Arthritis: Comparing 200 mg and 1g Doses for Maintenance Treatment

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of 7% Hypertonic Saline Inhalation and ELTGOL Physiotherapy for Patients with Bronchiectasis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Neural Stem Cell and Sodium Chloride Treatment for Patients with Amyotrophic Lateral Sclerosis

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Safety and Effectiveness of mRNA-3927 for Patients with Propionic Acidemia

    Recruiting

    2 1 1 1
    Investigated drugs:
    France Italy The Netherlands Spain

  • Study on the Effectiveness and Safety of Rituximab for Patients with Progressive Interstitial Lung Disease with Inflammation

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Efficacy of Sivelestat in Patients with Septic Coagulopathy: A Phase IIb Randomized Controlled Trial

    Not yet recruiting

    2 1 1
    Investigated drugs:
    France

  • Study of Isoprenaline and Epinephrine Treatment for Patients with Out-of-Hospital Cardiac Arrest with Non-Shockable Rhythm

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • A Study of Donanemab in People With Early Symptomatic Alzheimer’s Disease

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Poland Spain

Glossary

  • Interstitial Lung Disease (ILD): A group of disorders causing inflammation and scarring of lung tissue, leading to breathing difficulties.
  • Propionic Acidemia (PA): A rare genetic disorder where the body can't break down certain parts of proteins and fats properly, leading to a buildup of toxic substances.
  • Forced Vital Capacity (FVC): The total amount of air exhaled during a forced breath, used to assess lung function.
  • Rituximab: An antibody treatment that targets certain immune cells, used in the ILD trial to potentially reduce inflammation.
  • mRNA-3927: An experimental treatment for PA that aims to provide instructions for making an enzyme that PA patients lack.
  • Metabolic Decompensation Event (MDE): A serious health episode in PA patients where toxic substances build up, potentially causing organ damage.
  • Pharmacodynamics (PD): The study of how a drug affects the body.
  • Pharmacokinetics (PK): The study of how the body processes a drug.
  • Adverse Event (AE): Any unfavorable medical occurrence in a patient during a clinical trial.
  • Quality of Life (QoL): A measure of an individual's well-being and ability to carry out daily activities.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-rituximab-for-patients-with-progressive-interstitial-lung-disease-with-inflammation/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mrna-3927-for-patients-with-propionic-acidemia/